Monoclonal antibody therapy for severe asthma


Three monoclonal antibody therapies (benralizumab, mepolizumab and omalizumab) are available in Australia for the treatment of patients with severe asthma whose asthma is uncontrolled despite optimised standard treatment including high-dose inhaled corticosteroids and long-acting beta2 agonists (Table 1).

This information paper for health professionals provides a summary of the latest evidence on the prevalence and impact of poor technique, alongside checklists for correct use of the main inhalers available in Australia. It is not intended as a patient hand-out.


Bulk orders

We have limited stock of our print resources so please only order the quantities that you need.

If you are ordering for a clinic and require large quantities of this resource, please contact us via email with your request.